No Data
Is Tenet Healthcare (NYSE:THC) A Risky Investment?
Goldman Sachs Maintains Tenet Healthcare(THC.US) With Hold Rating, Raises Target Price to $154
Tenet Healthcare Poised to Benefit From Outpatient Growth Due to ASC Leadership, Morgan Stanley Says
Express News | Goldman Sachs Maintains Neutral on Tenet Healthcare, Raises Price Target to $154
Morgan Stanley Raises Price Target on Tenet Healthcare to $175 From $165, Keeps Overweight Rating
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?